剂量递增再程放疗改善局部复发头颈癌的疗效——一项大型多中心分析结果
这项多中心回顾性分析纳入2009至2020年德国16所大学医院收治的253例局部区域复发或第二原发头颈鳞癌患者,评估再程放疗的疗效与预后因素。中位随访27.4个月,中位总生存13.2个月、无进展生存7.9个月。多因素分析显示良好ECOG体能状态与高放疗剂量是总生存的独立预后因素,EQD2超过50 Gy者中位总生存17.8个月 vs 11.7个月(p<0.01)。
要点
- 253例局部区域复发或第二原发头颈鳞癌患者接受现代放疗技术再程放疗,中位随访27.4个月。
- 中位总生存13.2个月,中位无进展生存7.9个月,两年总生存率29%、无进展生存率19%。
- EQD2超过50 Gy者中位总生存17.8个月 vs 11.7个月(p<0.01),中位无进展生存9.6个月 vs 6.8个月(p<0.01)。
核心结论
- 局部复发或第二原发头颈鳞癌的再程放疗有效,尤其在EQD2超过50 Gy时。
- ECOG体能评分是总生存和无进展生存最强的预后参数。
研究设计与样本
- 多中心回顾性分析,纳入2009至2020年德国16所大学医院收治的253例局部区域复发或第二原发头颈鳞癌患者,接受现代放疗技术再程放疗。
- 主要终点为总生存、无进展生存和局部区域控制;单因素分析采用Kaplan-Meier法(log-rank检验),多因素分析采用Cox回归。
主要发现
- 中位随访27.4个月(范围0.5-130),中位总生存13.2个月(CI:10.7-15.7),中位无进展生存7.9个月(CI:6.7-9.1)。
- 两年总生存率和无进展生存率分别为29%和19%,两年局部区域进展率和野内失败率分别为62%和51%。
- EQD2超过50 Gy者中位总生存17.8个月 vs 11.7个月(p<0.01),中位无进展生存9.6个月 vs 6.8个月(p<0.01)。
- 多因素Cox回归分析确定良好ECOG体能状态和高放疗剂量为总生存的独立预后参数。
- 气管造口患者生存有更差的趋势(多因素分析,p=0.061);同期全身治疗对无进展生存或总生存无显著影响。
关键数值与推荐
- EQD2超过50 Gy者中位总生存17.8个月,EQD2不超过50 Gy者为11.7个月(p<0.01)。
- EQD2超过50 Gy者中位无进展生存9.6个月,EQD2不超过50 Gy者为6.8个月(p<0.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: To determine efficacy and prognostic parameters of definitive re-irradiation of locoregionally recurrent squamous cell carcinoma of the head and neck (HNSCC). MATERIALS AND METHODS: Patients with locoregionally recurrent or second primary HNSCC undergoing re-irradiation with modern radiotherapy technique were eligible for this multicentric retrospective analysis. Main endpoints were overall survival (OS), progression-free survival (PFS) and locoregional control (LC). Univariate analyses were performed using the Kaplan Meier Method (log-rank). For multivariable analysis, Cox regression was used. RESULTS: A total of 253 patients treated between 2009 and 2020 at 16 university hospitals in Germany were included. The median follow up was 27.4 months (range 0.5-130). The median OS and PFS were 13.2 (CI: 10.7 - 15.7) months and 7.9 (CI: 6.7 - 9.1) months, respectively, corresponding to two-year OS and PFS rates of 29 % and 19 %. Rates of locoregional progression and "in-field-failure" were 62 % and 51 % after two years. Multivariable Cox regression analysis identified good ECOG performance status and high radiation dose as independent prognostic parameters for OS. Doses above 50 Gy (EQD2) achieved longer median OS of 17.8 months (vs 11.7 months, p < 0.01) and longer PFS of 9.6 months (vs 6.8 months, p < 0.01). In addition, there was a trend for worse survival in patients with tracheostomy (multivariable, p = 0.061). Concomitant systemic therapy did not significantly impact PFS or OS. CONCLUSION: Re-irradiation of locally recurrent or second primary HNSCC is efficient, especially if doses above 50 Gy (EQD2) are delivered. ECOG performance score was the strongest prognostic parameter for OS and PFS.
引用
- Roesch J, Oertel M, Wegen S, et al. Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer - Results of a large multicenter analysis. Radiother Oncol. 2022. PMID: 36273736. doi:10.1016/j.radonc.2022.10.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。